The leader in needle-free auto-injection for life-threatening emergency situations

CROSSJECT is a specialty pharmaceutical company revolutionizing the delivery of rapid-acting emergency medications through ZENEO®, its safe and reliable needle-free auto-injector designed for critical situations.

See ZENEO® in action

Epileptic seizure

À l’échelle mondiale, environ 65 millions de personnes vivent avec l’épilepsie, dont environ
40% souffrent de crises réfractaires, qui restent incontrôlées malgré des traitements chroniques.

Adrenal crisis

À l’échelle mondiale, environ 65 millions de personnes vivent avec l’épilepsie, dont environ
40% souffrent de crises réfractaires, qui restent incontrôlées malgré des traitements chroniques.

Allergic shock

À l’échelle mondiale, environ 65 millions de personnes vivent avec l’épilepsie, dont environ
40% souffrent de crises réfractaires, qui restent incontrôlées malgré des traitements chroniques.

ZENEO® is a needle-free, pre-filled, single-use auto-injector

NEEDLE-FREE, FAST, RELIABLE,SAFE, AND VERY EASY TO USE

ZENEO®
Technology

The ZENEO® technology is the foundation of our innovative solutions

Learn more about the technology

THERAPEUTIC AREAS

Our product pipeline

**Acute Adrenal Crisis (AAC)** is a potentially life-threatening condition classified as a rare disease, with a prevalence of approximately 5 people per 10,000 in the United States and Europe.

Acute adrenal insufficiency

Globally, approximately 65 million people live with epilepsy, of whom around 40% experience refractory seizures that remain uncontrolled despite chronic treatments.

Epileptic seizure

Other products in the pipeline
Anaphylaxis is a severe and potentially life-threatening allergic reaction that requires immediate emergency treatment to prevent fatal outcomes.

Allergic shock

Other products in the pipeline

ABOUT CROSSJECT

CROSSJECT is revolutionizing drug delivery

INVESTORS

Press Releases

Read more

Our News

Read more

Newsletter

Read more

Send us a message

Pages

Follow us

Informations

Newsletter

Copyright © 2024 CROSSJECT – VERSION BETA TEST